Research Triangle Park’s TransEnterix (NYSE MKT: TRXC) cut ties with an estimated 50 employees in the United States – about 40 percent of its workforce in this country – something company CFO Joseph Slattery said will result “in an annualized reduction in salaries of approximately $4 million.”
TransEnterix had developed a robot to assist surgeons in minimally invasive surgery called SurgiBot. However, the U.S Food and Drug Administration denied TransEnterix’s application for approval of the device.
TransEnterix had developed a robot to assist surgeons in minimally invasive surgery called SurgiBot. However, the U.S Food and Drug Administration denied TransEnterix’s application for approval of the device.
